Atypical Ductal Hyperplasia (ADH) of the Breast
Conditions
Brief summary
This study is designed to look at whether it is feasible to observe women with atypical ductal hyperplasia (ADH) of the breast, or whether surgical excision is necessary.
Detailed description
We hypothesize that surgical excision may not yield an improvement in survival over hormonal therapy and/or close observation alone in patients who present with ADH on core needle biopsy of the breast. An alternate (non-inferior) strategy for management may be possible, and may be associated with improved quality of life and fewer complications, and lower overall costs. Although several researchers have suggested a clinical trial to investigate this idea this would be the first time it has been done, and could therefore be practice changing.
Interventions
None listed
Sponsors
Yale University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
A patient/subject is eligible for enrollment if all of the following inclusion criteria are met: 1. Pre- and post-menopausal women ≥ 40 years of age with newly diagnosed ADH, histologically confirmed on breast core biopsy. 2. Ability to understand and the willingness to sign a written informed consent document. 3. Willing to schedule definitive resection of ADH if randomized to surgical excision arm or be observed if randomized to the observation arm. 4. Original breast core biopsy specimen available for pathologic review and staining by Yale School of Medicine Department of Pathology.
Exclusion criteria
A patient/subject will not be eligible for this study if any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Findings of palpable mass or imaging abnormality (increase in size or in the amount of calcifications) | 5 years | Findings of palpable mass or imaging abnormality (increase in size or in the amount of calcifications) in the observation period will be subject to biopsy; pathology results indicating in situ or invasive disease will prompt multi-disciplinary treatment consistent with established standards of care.Patients in the close observation group will be assessed at six months and annually thereafter with clinical examination and breast imaging. Patients in the surgery group will be followed with yearly clinical breast exam and yearly breast imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life, patient satisfaction and costs between the two groups will be measured by the Functional Assessment of Chronic Illness Therapy (FACIT), specifically the FACT-G and the FACT-Es. | 5 years | The FACT-GP will measure physical well-being, social/family well-being, emotional well-being and functional well-being. Higher scores indicate better well-being. The FACT-Es will be used to assess symptoms related to menopause and tamoxifen or exemestane, as we anticipate many of the subjects will be on endocrine therapy as part of their chemo-prevention. |
Countries
United States
Outcome results
None listed